Amanda Ei Proudfoot

Summary

Affiliation: Merck Serono
Country: Switzerland

Publications

  1. doi The use of chemokine antagonists in EAE models
    Amanda E I Proudfoot
    Merck Serono Geneva Research Centre, 9 Chemin des Mines, Geneva, Switzerland
    J Neuroimmunol 198:27-30. 2008
  2. doi Anti-chemokine small molecule drugs: a promising future?
    Amanda E I Proudfoot
    Merck Serono Geneva Research Center, Merck Serono International SA, 9 Chemin des Mines, 1202 Geneva, Switzerland
    Expert Opin Investig Drugs 19:345-55. 2010
  3. pmc Ticks produce highly selective chemokine binding proteins with antiinflammatory activity
    Maud Deruaz
    Merck Serono Geneva Research Centre, 1202 Geneva, Switzerland
    J Exp Med 205:2019-31. 2008
  4. pmc An engineered monomer of CCL2 has anti-inflammatory properties emphasizing the importance of oligomerization for chemokine activity in vivo
    Tracy M Handel
    Merck Serono Geneva Research Centre, Geneva, Switzerland
    J Leukoc Biol 84:1101-8. 2008
  5. ncbi Molecular cloning and characterization of a highly selective chemokine-binding protein from the tick Rhipicephalus sanguineus
    Achim Frauenschuh
    Merck Serono Geneva Research Centre, 9 Chemin des Mines, CH 1211 Geneva, Switzerland
    J Biol Chem 282:27250-8. 2007
  6. pmc CCR5 deficiency drives enhanced natural killer cell trafficking to and activation within the liver in murine T cell-mediated hepatitis
    Maureen N Ajuebor
    Department of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, Canada
    Am J Pathol 170:1975-88. 2007
  7. ncbi Differential effects of chemokines on oligodendrocyte precursor proliferation and myelin formation in vitro
    Linda Kadi
    Department of Immunology, Serono Pharmaceutical Research Institute 14, Chemin des Aulx, 1228 Plan les Ouates, Geneva, Switzerland
    J Neuroimmunol 174:133-46. 2006
  8. ncbi Chemokine blockers--therapeutics in the making?
    Timothy N C Wells
    Serono Pharmaceutical Research Institute, 1228 Plan les Ouates, Geneva, Switzerland
    Trends Pharmacol Sci 27:41-7. 2006
  9. ncbi Multi-faceted strategies to combat disease by interference with the chemokine system
    Zoe Johnson
    Serono Pharmaceutical Research Institute, 14 Chemin des Aulx, 1228 Plan les Ouates, Geneva, Switzerland
    Trends Immunol 26:268-74. 2005
  10. ncbi Chemokines bind to sulfatides as revealed by surface plasmon resonance
    Roger Sandhoff
    German Cancer Research Center, Department of Cellular and Molecular Pathology, INF 280, 69120 Heidelberg, Germany
    Biochim Biophys Acta 1687:52-63. 2005

Collaborators

  • Roger Sandhoff
  • Maureen N Ajuebor
  • Richard Ransohoff
  • C M Hogaboam
  • Christian Weber
  • Timothy N C Wells
  • Maud Deruaz
  • Christine A Power
  • Jeffrey P Shaw
  • Zoe Johnson
  • Mauro M Teixeira
  • Achim Frauenschuh
  • Tracy M Handel
  • Beatriz R Ferreira
  • Joao M Dias
  • Linda Kadi
  • Frederic Borlat
  • Philipp von Hundelshausen
  • James J Yun
  • Niels R Veillard
  • Masaru Matsui
  • Simona Riva
  • Pierre Alain Vitte
  • David H Rodrigues
  • Remo C Russo
  • Rocco Cirillo
  • Valeria Muzio
  • Ana L Alessandri
  • Gerard J Graham
  • Adriana C Dos Santos
  • Fernanda M Coelho
  • Matthias Mack
  • Thierry Martin
  • Joao S Silva
  • Ursula Boschert
  • Ram Selvaraju
  • Patricia de Lys
  • Rory R Koenen
  • Wencke Adriaens
  • Sebastian F Mause
  • Matthias Schwarz
  • Markus Sack
  • Tilman M Hackeng
  • Hillel Laks
  • Abbas Ardehali
  • Francois Mach
  • Judith A Berliner
  • Catherine Zwahlen
  • Yoshihito Irie
  • Anamika Banerji
  • Richard W James
  • Brenda Kwak
  • Michael P Fischbein
  • Flore Mulhaupt
  • David Whiting
  • Andreas Kungl
  • Axel Harrenga
  • Graziano Pelli
  • Karen Roulin
  • Daniel Stein
  • Michael C Fishbein
  • Edward Richer
  • Ashwin Rao
  • Jerome R Wujek
  • Tao Wei
  • Jennifer Weaver
  • Bruce D Trapp

Detail Information

Publications19

  1. doi The use of chemokine antagonists in EAE models
    Amanda E I Proudfoot
    Merck Serono Geneva Research Centre, 9 Chemin des Mines, Geneva, Switzerland
    J Neuroimmunol 198:27-30. 2008
    ..We will discuss these strategies and their successes and failures to prevent disease symptoms and the insights they have provided...
  2. doi Anti-chemokine small molecule drugs: a promising future?
    Amanda E I Proudfoot
    Merck Serono Geneva Research Center, Merck Serono International SA, 9 Chemin des Mines, 1202 Geneva, Switzerland
    Expert Opin Investig Drugs 19:345-55. 2010
    ..Chemokines activate seven transmembrane G protein-coupled receptors, making them extremely attractive therapeutic targets for the pharmaceutical industry...
  3. pmc Ticks produce highly selective chemokine binding proteins with antiinflammatory activity
    Maud Deruaz
    Merck Serono Geneva Research Centre, 1202 Geneva, Switzerland
    J Exp Med 205:2019-31. 2008
    ..and P.J. Hudson. 2005. Nat. Biotechnol. 23:1126-1136), and may be therapeutically useful as novel antiinflammatory agents in the future...
  4. pmc An engineered monomer of CCL2 has anti-inflammatory properties emphasizing the importance of oligomerization for chemokine activity in vivo
    Tracy M Handel
    Merck Serono Geneva Research Centre, Geneva, Switzerland
    J Leukoc Biol 84:1101-8. 2008
    ..These results suggest that oligomerization-deficient chemokines can exhibit anti-inflammatory properties in vivo and may represent new therapeutic modalities...
  5. ncbi Molecular cloning and characterization of a highly selective chemokine-binding protein from the tick Rhipicephalus sanguineus
    Achim Frauenschuh
    Merck Serono Geneva Research Centre, 9 Chemin des Mines, CH 1211 Geneva, Switzerland
    J Biol Chem 282:27250-8. 2007
    ....
  6. pmc CCR5 deficiency drives enhanced natural killer cell trafficking to and activation within the liver in murine T cell-mediated hepatitis
    Maureen N Ajuebor
    Department of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, Canada
    Am J Pathol 170:1975-88. 2007
    ..These results highlight the potential profound impact of altered chemokine receptor expression on the innate immune response in the setting of T cell-mediated hepatitis...
  7. ncbi Differential effects of chemokines on oligodendrocyte precursor proliferation and myelin formation in vitro
    Linda Kadi
    Department of Immunology, Serono Pharmaceutical Research Institute 14, Chemin des Aulx, 1228 Plan les Ouates, Geneva, Switzerland
    J Neuroimmunol 174:133-46. 2006
    ..We propose, therefore, that CXC chemokines and in particular SDF-1alpha regulates CNS myelination via their effects on cells of the oligodendrocyte lineage, specifically stimulation of OLP proliferation...
  8. ncbi Chemokine blockers--therapeutics in the making?
    Timothy N C Wells
    Serono Pharmaceutical Research Institute, 1228 Plan les Ouates, Geneva, Switzerland
    Trends Pharmacol Sci 27:41-7. 2006
    ..Here, we describe the rationale behind these different approaches, the pitfalls that have been encountered and future perspectives...
  9. ncbi Multi-faceted strategies to combat disease by interference with the chemokine system
    Zoe Johnson
    Serono Pharmaceutical Research Institute, 14 Chemin des Aulx, 1228 Plan les Ouates, Geneva, Switzerland
    Trends Immunol 26:268-74. 2005
    ..The object of this Review is to discuss the validity and feasibility of targeting several points of therapeutic intervention offered by the chemokine system and to assess the state of play within the field to date...
  10. ncbi Chemokines bind to sulfatides as revealed by surface plasmon resonance
    Roger Sandhoff
    German Cancer Research Center, Department of Cellular and Molecular Pathology, INF 280, 69120 Heidelberg, Germany
    Biochim Biophys Acta 1687:52-63. 2005
    ....
  11. ncbi The X-ray structure of RANTES: heparin-derived disaccharides allows the rational design of chemokine inhibitors
    Jeffrey P Shaw
    Serono Pharmaceutical Research Institute, 14 Chemin des Aulx, 1228 Plan les Ouates, Geneva, Switzerland
    Structure 12:2081-93. 2004
    ..These crystallographic structures provide a description of the molecular interaction of a chemokine with glycosaminoglycans...
  12. ncbi Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium
    Philipp von Hundelshausen
    Department of Molecular Cardiovascular Research, University Hospital Aachen, Germany
    Blood 105:924-30. 2005
    ..This may have implications for the modulation of inflammatory recruitment by platelet-derived chemokines...
  13. ncbi CCL3/MIP-1alpha is pro-inflammatory in murine T cell-mediated hepatitis by recruiting CCR1-expressing CD4(+) T cells to the liver
    Maureen N Ajuebor
    Liver Unit, Gastrointestinal Research Group, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
    Eur J Immunol 34:2907-18. 2004
    ..These findings demonstrate that blockade of the CCL3/MIP-1alpha-CCR1 pathway may represent a novel therapeutic target for treating T cell-mediated liver diseases...
  14. ncbi Combined blockade of the chemokine receptors CCR1 and CCR5 attenuates chronic rejection
    James J Yun
    Department of Surgery, Division of Cardiothoracic Surgery, University of California at Los Angeles, Los Angeles, Calif, USA
    Circulation 109:932-7. 2004
    ..In this study, we sought to determine whether blockade of chemokine receptors CCR1 and CCR5 with Met-RANTES affects the development of CAV in a murine model...
  15. ncbi Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice
    Niels R Veillard
    Division Cardiology, Foundation for Medical Research, University Hospital Geneva, Geneva, Switzerland
    Circ Res 94:253-61. 2004
    ..Thus, our findings indicate that blockade of chemokine receptor/ligand interactions might become a novel therapeutic strategy to reduce the evolution of this common disease...
  16. pmc Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines
    Amanda E I Proudfoot
    Serono Pharmaceutical Research Institute, 14 Chemin des Aulx, 1228 Plan les Ouates, Geneva, Switzerland
    Proc Natl Acad Sci U S A 100:1885-90. 2003
    ..Thus, quaternary structure of chemokines and their interaction with GAGs may significantly contribute to the localization of leukocytes beyond migration patterns defined by chemokine receptor interactions...
  17. ncbi Strategies for chemokine antagonists as therapeutics
    Amanda E I Proudfoot
    Serono Pharmaceutical Research Institute, 14 Chemin des Aulx, 1228 Plan les Ouates, Geneva, Switzerland
    Semin Immunol 15:57-65. 2003
    ..We summarize the status of the approaches that have been undertaken to produce therapeutics that block chemokine action...
  18. ncbi Treatment of experimental autoimmune encephalomyelitis with the chemokine receptor antagonist Met-RANTES
    Masaru Matsui
    Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Neuroimmunol 128:16-22. 2002
    ..Further analysis of the effects of chemokine receptor blockade may need to focus on leukocyte activation within the affected CNS as well as trafficking events...
  19. ncbi Chemokine receptors: multifaceted therapeutic targets
    Amanda E I Proudfoot
    Serono Pharmaceutical Research Institute, 14 Chemin des Aulx, 1228 Plan les Ouates, Geneva, Switzerland
    Nat Rev Immunol 2:106-15. 2002
    ..Here, I focus on the rationale for developing antagonists of chemokine receptors for inflammatory disorders and AIDS, and the accumulating evidence that favours this strategy despite the apparent redundancy in the chemokine system...